Turner syndrome: effect of hormone therapies on height velocity and adult height.
76 patients with Turner syndrome received estrogen alone, androgen and estrogen started simultaneously or, after preceding androgen therapy, estrogen with or without androgen. Six patients had spontaneous pubertal development and received no estrogen. Two patients received human growth hormone with androgen during greater than 2.0 years. Height velocity increased during all therapies to mean SD scores of 7.6 during androgen-estrogen started simultaneously, 4.6 during androgen alone, 4.2 during androgen-estrogen after preceding androgen, 2.7 during estrogen alone, and 0.6 during estrogen after preceding androgen. Adult height was measured in all cases, it was 145.5 +/- 5.7 (mean +/- SD) for the whole series without significant differences between the groups. It correlated strongly with midparent height, and was greater for patients with the 45,X karyotype than for the others combined.
Lenko
H L
HL
Department of Pediatrics, University Hospital, Tampere, Finland.
Söderholm
A
A
Perheentupa
J
J
D000293:Adolescent; D001827:Body Height / Q000187:drug effects; D002648:Child; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D005474:Fluoxymesterone / Q000627:therapeutic use; D006128:Growth / Q000187:drug effects*; D006801:Humans; D008655:Mesterolone / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use; D014424:Turner Syndrome / Q000188:drug therapy*
D011372:Progestins; D008655:Mesterolone; D004958:Estradiol; D005474:Fluoxymesterone